Pfizer and Novo Nordisk’s $10 Billion Obesity Drug Battle
The bidding war for obesity biotech Metsera has escalated dramatically, with Novo Nordisk now offering up to $10 billion versus Pfizer’s $8.1 billion revised bid. Pfizer has filed two lawsuits alleging anticompetitive behavior while Metsera calls the legal arguments “nonsense.”